Fei Wang¹, Jihyun Ma², Nan Zhao³, Chi Lin^3,*, Haixing Jiang^1,*

Oncologie, Vol.24, No.4, pp. 865-895, 2022, DOI:10.32604/oncologie.2022.025447

Abstract Objective: The characteristics of clinical features and prognoses among patients with different racial backgrounds have not been clearly studied. We thus investigated the clinical characteristics and overall survival (OS) differences among Asian, White, and Black patients with pancreatic neuroendocrine tumors (pNETs). Materials and Methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried to identify patients with pNETs between 1983 and 2015. We performed univariable (UVA) and multivariable logistic regression (MVA) to assess the association between variables and race category. A Kaplan-Meier (KM) plot was used to calculate the OS rates. The Cox proportional hazard regression was used to… More >

J.-Y. Scoazec

Oncologie, Vol.21, No.2, pp. 119-124, 2019, DOI:10.3166/onco-2019-0052

Abstract The WHO classification of the tumors of endocrine organs, published in July 2017 and that of digestive tumors, released in July 2019, have introduced significant changes in the classification of gastro-entero-pancreatic neuroendocrine tumors (NETs), which was unchanged since 2010. The main change is a new category of well-differentiated neoplasms, NET G3, in addition to the two previous categories NET G1 and NET G2. The other changes are: 1) the cut-off in Ki-67 index between NET G1 and G2, now set at 3%, 2) the term used for mixed tumors: MiNEN (mixed neuroendocrine-non neuroendocrine neoplasm) instead of MANEC (mixed adenoneuroendocrine carcinoma).… More >